• Expression levels of IL4R are low on the surface of healthy and normal cells, but increase several fold on cancer cells and non-malignant cells of the TME
  • Analysis of over 2,000 cancer biopsies, shows that the IL-4R is over-expressed in 20 different types solid and hematological cancers corresponding to an annual incidence rate of over a million IL4R positive cancers
  • The IL-4/IL-4R axis plays a prominent role in supporting the establishment and maintenance of a robust TME, thereby protecting the cancer from the body’s own immune system and immunotherapies
  • The IL-4/IL-4R bias continues to be identified as a marker for highly aggressive forms of cancer and is generally associated with poor survival outcomes
  • Cancer stem cells also thrive in the presence of IL-4